Jefferies Global Healthcare Conference
Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Beam Therapeutics Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

BEAM-302 and alpha-1 antitrypsin deficiency

  • BEAM-302 is in a pivotal accelerated-approval cohort; enrollment is swift, with the 50th dose expected in H1 2027, followed by 12 months of follow-up and a filing package.

  • Trial spans six countries and 15+ enrolling sites; screen failures are low and predictable, with similar recruitment rates in the U.S. and ex-U.S.

  • The intended pivotal population includes patients with lung disease, with or without liver involvement; more than 90% of patients fall within this broad label.

  • Reported data showed 90%+ corrected M protein, reduced Z protein and inducible expression; one infection case showed AAT rising from the mid-teens to 25 micromolar.

  • Additional updates are expected to include liver biopsies, BAL fluid, CT densitometry, FEV1 and patient-reported outcomes; no interim disclosure is planned for the 50-patient pivotal cohort.

Regulatory path and competitive position

  • FDA feedback calls for 12 months of pivotal follow-up; earlier engagement could be considered if data show a robust, stable benefit, but the current plan remains a 12-month dataset.

  • CT densitometry is the preferred confirmatory endpoint; SPARTA results expected by year-end 2026 may inform its use, while FEV1 and St. George's Respiratory Questionnaire remain alternatives.

  • Management described a multi-year lead in alpha-1 clinical experience and plans to build payer and site relationships; LNP delivery is viewed as scalable for broad treatment after launch.

Risto-cel and sickle cell opportunity

  • Risto-cel BLA writing is being finalized, with filing on track for December 2026; approval could come in Q3 2027 with Priority Review or December 2027 under standard review.

  • Management cited projected 2026 sales above $700M for the two marketed sickle cell gene therapies and forecast a $1B+ category starting in 2027.

  • Risto-cel differentiation includes 60% fetal hemoglobin and 40% sickle hemoglobin, faster engraftment by several days, full anemia resolution and median single-round mobilization in BEACON.

  • Commercial preparation includes patient-journey tracking, hospital coordination and a modest field footprint focused on large U.S. centers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Beam Therapeutics